Chronic, recurrent Lymphocytic Leukemia Terminated Phase 1 Trials for Ibrutinib (DB09053)
Also known as: Recurrent Chronic Lymphocytic Leukemia
| Indication | Status | Phase |
|---|---|---|
| DBCOND0112002 (Chronic, recurrent Lymphocytic Leukemia) | Terminated | 1 |
| clinicaltrials.gov Identifier | Title | Purpose | Drugs |
|---|---|---|---|
| NCT02614508 | Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia | Treatment |